HEALTHCARE & PHARMACEUTICALS MARKET RESEARCH
Tag: covid-19
-
Paxlovid: The Ultimate Antiviral Pill
Introduction Paxlovid, the pill that has become the go-to treatment for COVID-19 treatment, was granted full approval in May by the Food And Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease, including hospitalization and death. The drug also remains available to everyone 12 and older (weighing at…
-
HERE’S WHAT WE KNOW ABOUT COVID-19 AND AUTOIMMUNITY
Before we get into understanding the possible links between autoimmunity and COVID-19, it is imperative that we understand what autoantibodies are and how they affect our body. These self-attacking antibodies are produced by the immune system and are pathogenic in nature as they can destroy the antigens and other substances such as carbohydrate,proteins, etc. made by…
-
ACTIVE COVID-19 CASES CROSS THE 2 LAKH MARK IN KERALA
With a daily count of over 30,000 cases for the fourth consecutive day, Kerala accounts for around 70% of he total COVID-19 cases in the country. Active cases are over 2 lakhs and the latest positivity rate recorded on a day was 18.67%. “Since the relaxations in lockdown, there has been surge in cases. It was further increased after Onam,” says Vijayan…
-
INDIA ADMINISTERED OVER 32 CRORE DOSES, OVERTAKES US
Health ministry on Monday informed that as many as 32.8 crore doses of Covid-19 vaccines have been administered since the start of the vaccination drive that began from January 16. Out of these, one crore healthcare workers took the first dose and 72 lakh got the second dose as well. Following a new policy, India has…
-
ZYDUS CADILA’S VACCINE TO BE JUST AS EFFECTIVE WITH A TWO- DOSE REGIMEN
Highlights: Fifth vaccine to be authorized in India. Now effective with two doses. Company to manufacture 120M doses a year. If approved, it could be World’s first plasmid DNA shot. Zydus Cadila, a leading Indian Pharmaceutical company is seeking approval from the DCGI for the EUA of its Covid-19 vaccine candidate, ZyCoV-D. It is the…
-
SII TO SUPPLY 20 CRORE COVAVAX DOSES BY DEC 2021
The Maryland based company, Novavax’s covid-19 vaccine candiate, named Covavax in India is all set to be launched in August-September this year in association with the Pune based Serum Institute of India. The vaccine has shown 90% efficacy in the clinical trials conducted in the U.S. With U.S. easing the availability of the key raw…
-
FIRST DEATH FOLLOWING COVID-19 VACCINATION
A 68 year old man has died after being fully vaccinated with the covishield vaccine in the month of March due to anaphylaxis, which is considered as a severe allergic reaction that could happen post vaccination. In a report submitted by the AEFI Committee, it has been reported that the cause of death is a…
-
HOW LIKELY IS THE THIRD WAVE IN INDIA?
Several speculations are doing the rounds regarding the possibility of a third wave and if children are at a risk of getting infected in the subsequent wave. There is a lot of misinformation involved; however certain things need to be understood and implemented accurately so that we can look towards a foreseeable post pandemic future…
-
Concern of rising SARS-CoV2 Variants and Mutations
As new variants of SARS-Cov2 the official title given to the COVID-19 virus, continue to arise, similar transformations are discovered by the scientists, making the infection more problematic and destructive. This article primarily focuses on those changes called mutations. What happens during mutations? Once a virus gets into our body, it latches onto one of…
-
GOVERNMENT TO RESERVE 30 CRORE DOSES OF BIOLOGICAL E’S NEW VACCINE
Biological E, a Hyderabad-based vaccine and pharmaceutical company, has announced that it has successfully completed the Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India called Corbevax and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organization (CDSCO) – Subject Expert Committee (SEC). The…
Follow Us
Recent Posts
-
Bedaquiline Role in Treating Tuberculosis having a hefty $1.38 billion dollar market
-
Adalimumab’s competition and immense market Growth Potential of 5.1%
-
Semaglutide’s massive influence on the Diabetes Pharmaceutical Market and 6 competitors
-
FDA approved Leqembi to have $12.9 billion sales
-
Assistive Technology Market; a $82B Growth Story
Tags
Autoimmunity cancer cancer research cancer therapy CDSCO covid-19 covid in children Diabetes drug Elderly Health FDA healthcare immune response Kerala mutations Nipah virus pandemic PCOS pharma Pharmaceutical market pharma sector protein-based vaccines sars-cov-2 therapy third wave Treatment vaccine variants WHO zydus cadila